Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
C4X Discovery
AI-generated illustration
OrganisationGB

C4X Discovery

Manchester drug-discovery company, spun out of the University of Manchester in 2007.

C4X Discovery is a Manchester drug-discovery company spun out of the university in 2007. On 4 September 2026 it earned a $13m milestone payment when AstraZeneca moved its licensed compound AZD4916 into a Phase 1 trial.

Last refreshed: 22 September 2026 · Appears in 1 active topic

Timeline for C4X Discovery

#15 4 Sept

Earned a USD13 million milestone payment from AstraZeneca

UK Startups and Innovation: C4X banks $13m as AstraZeneca doses
View full timeline →
Follow UK Startups and Innovation →

Background

C4X Discovery is an AIM-listed drug-discovery company (LSE: C4XD) headquartered in Manchester, using its Taxonomy3 computational chemistry platform to design small-molecule drug candidates. The company was spun out of the University of Manchester in 2007 as C4X Discovery Limited (Companies House no. 06324250); a holding company, C4X Discovery Holdings Limited, was incorporated in 2014 ahead of its AIM listing.

On 4 September 2026 it earned a $13m milestone payment when licensing partner AstraZeneca moved compound AZD4916 into a Phase 1 trial, under a deal worth up to $400m plus tiered royalties.

C4X Discovery exemplifies the UK's asset-light biotech model, earning revenue from milestone and royalty payments on licensed compounds rather than running its own late-stage clinical trials, and forms part of Manchester's life-sciences cluster.

Common Questions
Is C4X Discovery based in Leeds or Manchester?
C4X Discovery is headquartered in Manchester, having spun out of the University of Manchester in 2007. It is not a Leeds company; MicroLub, a separate University of Leeds spinout, is sometimes reported alongside it.
Why did C4X Discovery receive a $13m payment from AstraZeneca?
AstraZeneca moved C4X Discovery's licensed compound AZD4916 into a Phase 1 clinical trial on 4 September 2026, which triggered a $13m milestone payment under their licensing deal.Source: event
How much could C4X Discovery's AstraZeneca licence be worth?
The licence for AZD4916 could be worth up to $400m plus tiered mid-single-digit royalties, though most of that value depends on the compound clearing further clinical trials.Source: event
What is C4X Discovery's Taxonomy3 platform?
Taxonomy3 is C4X Discovery's computational chemistry platform, which it uses to design small-molecule drug candidates that it then licenses to larger pharmaceutical partners such as AstraZeneca.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 22 September 2026. Editorial standards.